Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Oliva

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Oral Oncology|April 10, 2020
Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapyMarc Oliva, Shao Hui Huang, Rachel Taylor, et al.
Frontiers in Oncology|August 8, 2022
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based ChemotherapyJuan A Marín-Jiménez, Marc Oliva, Paloma Peinado Martín, et al.
Nature Communications|December 10, 2024
Enhanced warming of European mountain permafrost in the early 21st centuryJeannette Noetzli, Ketil Isaksen, Jamie Barnett, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2019
Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapyMarc Oliva, Shao Hui Huang, Wei Xu, et al.
British Journal of Cancer|May 7, 2024
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 studyMarc Oliva, Alya Heirali, Geoffrey Watson, et al.
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
British Journal of Cancer|March 22, 2021
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study)Marc Oliva, Pierre H H Schneeberger, Victor Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapyMaria Jove, Irene Braña, Marc Oliva, et al.
Oral Oncology|November 23, 2025
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 studyKevin J Harrington, Ari J Rosenberg, Muh-Hwa Yang, et al.
The Laryngoscope|August 26, 2025
Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled AnalysisMilica Stefanovic, Alberto Hernando-Calvo, Jesus Brenes Castro, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Oral Oncology|April 10, 2020
Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapyMarc Oliva, Shao Hui Huang, Rachel Taylor, et al.
Frontiers in Oncology|August 8, 2022
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based ChemotherapyJuan A Marín-Jiménez, Marc Oliva, Paloma Peinado Martín, et al.
Nature Communications|December 10, 2024
Enhanced warming of European mountain permafrost in the early 21st centuryJeannette Noetzli, Ketil Isaksen, Jamie Barnett, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2019
Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapyMarc Oliva, Shao Hui Huang, Wei Xu, et al.
British Journal of Cancer|May 7, 2024
Prospective manipulation of the gut microbiome with microbial ecosystem therapeutic 4 (MET4) in HPV-related locoregionally-advanced oropharyngeal cancer squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation: ROMA2 studyMarc Oliva, Alya Heirali, Geoffrey Watson, et al.
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
British Journal of Cancer|March 22, 2021
Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study)Marc Oliva, Pierre H H Schneeberger, Victor Rey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2026
Phase I trial of intravenous VCN-01 oncolytic adenovirus and durvalumab in patients with head and neck metastatic squamous cell carcinoma refractory to immunotherapyMaria Jove, Irene Braña, Marc Oliva, et al.
Oral Oncology|November 23, 2025
Subcutaneous amivantamab in recurrent/metastatic head and neck squamous cell cancer after disease progression on checkpoint inhibitor and chemotherapy: Preliminary results from the phase 1b/2 OrigAMI-4 studyKevin J Harrington, Ari J Rosenberg, Muh-Hwa Yang, et al.
The Laryngoscope|August 26, 2025
Prognostic Factors in Sinonasal Cancers: A Multicenter Pooled AnalysisMilica Stefanovic, Alberto Hernando-Calvo, Jesus Brenes Castro, et al.
Pageof 7